Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13632816 | 0.89 | CARM1 (0.40) | MEN1KMT2AMAPTMAPK1NPSR1 | |
| SCHEMBL4018263 | 0.82 | ADRB2 (0.34) | MEN1KMT2ASLC8A1MAPTMAPK1 | |
| SCHEMBL13632933 | 0.79 | MAOB (0.33) | MEN1KMT2AMAPTMAPK1L3MBTL1 | |
| SCHEMBL13632805 | 0.76 | LPAR1 (0.34) | — | |
| SCHEMBL13632814 | 0.74 | CARM1 (0.39) | — | |
| SCHEMBL4020149 | 0.70 | CARM1 (0.41) | MEN1KMT2AMAPTMAPK1NPSR1 | |
| SCHEMBL4014221 | 0.70 | MEN1 (0.36) | MEN1KMT2AMAPTMAPK1NPSR1 | |
| SCHEMBL3701085 | 0.67 | OPRM1 (0.47) | MAPTMAPK1NPSR1L3MBTL1HDAC1 | |
| SCHEMBL6186185 | 0.63 | ROCK2 (0.46) | — | |
| SCHEMBL3694044 | 0.61 | OPRM1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618996-B2 | Diaryl ether derivatives and uses thereof | PFIZER INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | PFIZER INC | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | OPRD1, OPRK1, OPRL1 | MEN1 4729/4885KMT2A 1698/4885SLC8A1 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.